Drug Profile
Research programme: alpha-emitting radiolabelled antibodies - Actinium Pharmaceuticals/Philogen
Alternative Names: Ac-225-L19; L19-actinium-225-conjugateLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Actinium Pharmaceuticals; Philogen
- Class Monoclonal antibodies; Radioisotopes; Radiopharmaceuticals
- Mechanism of Action Angiogenesis inhibitors; Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Italy (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 29 Nov 2012 Preclinical trials in Cancer in Italy (Parenteral)